This study is composed of Phase I and Phase II part. Phase I part: The objective is to evaluate the safety of BMS-354825 in subject with chronic phase Chronic Myelogenous Leukemia (CML). Dosage of BMS-354825 will be 50 mg BID, 70 mg BID or 90 mg BID. Phase II part: The objective is to evaluate the efficacy of BMS-354825. dosage will be decided according to the results of Phase I part. Treatment period will be 6 months for subjects with chronic phase CML, and 3 months for subjects with accelerated phase or blast phase CML and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Inclusion Criteria:

• Philadelphia chromosome positive or bcr-abl gene positive
• Chronic Myelogenous Leukemia (CML)
• Subjects must have primary or acquired resistance to imatinib mesylate or have intolerance of imatinib mesylate
• Philadelphia Chromosome Positive Acute Lymphoblastic leukemia (Ph+ALL)
• Subjects must have primary or acquired resistance to chemotherapy or have intolerance of chemotherapy
• Performance status (general conditions) specified by the Eastern Cooperative Oncology Group: 0-2
• Men and women, ages 20 - 75
• Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 3 months after the study in such a manner that the risk of pregnancy is minimized

Exclusion Criteria:

• Subjects who are eligible and willing to undergo transplantation at pre-study
• Women who are pregnant or breastfeeding
• Uncontrolled or significant cardiovascular disease
• History of significant bleeding disorder unrelated to CML or ALL
• Adequate hepatic function
• Adequate renal function
• Medication that increase bleeding risk
• Medication that change heart rhythms
• Subjects who are compulsorily detained for legal reasons or treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study